All the news articles and press releases in one place.

Date / Time Source Company Sector Market Cap Announcement
04Oct19 07:00 RNS-R ANGLE plc Health £315.0m European patent granted for megakaryocyte analysis
13Sep19 07:00 RNS-R ANGLE plc Health £315.0m Use of Parsortix in head and neck cancer
10Sep19 07:00 RNS ANGLE plc Health £315.0m Research with Parsortix in prostate cancer
04Sep19 07:00 RNS-R ANGLE plc Health £315.0m Parsortix for Neuroendocrine Analysis in SCLC
29Aug19 07:00 RNS ANGLE plc Health £315.0m Initiation of Ovarian Cancer Study
31Jul19 07:00 RNS ANGLE plc Health £315.0m Prelim Results for the year ended 30 April 2019
22Jul19 07:00 RNS-R ANGLE plc Health £315.0m Use of Parsortix for single cell analysis of CTCs
16Jul19 09:19 RNS ANGLE plc Health £315.0m Holding(s) in Company
12Jul19 10:22 RNS ANGLE plc Health £315.0m Result of General Meeting anf Total Voting Rights
28Jun19 13:37 RNS ANGLE plc Health £315.0m Notice of Preliminary Results and Webcast
28Jun19 13:08 RNS ANGLE plc Health £315.0m Holding(s) in Company
25Jun19 17:19 RNS ANGLE plc Health £315.0m Result of Placing
25Jun19 08:02 RNS ANGLE plc Health £315.0m Accelerated bookbuild to raise £18.0m
21Jun19 07:00 RNS ANGLE plc Health £315.0m Parsortix used to investigate immunotherapy target
05Jun19 07:00 RNS ANGLE plc Health £315.0m Completion of Ovarian Cancer Pre-Study
31May19 07:00 RNS ANGLE plc Health £315.0m Positive Results from FDA Clinical Study
26Apr19 07:00 RNS ANGLE plc Health £315.0m IMMUNE SUPPRESSOR CELLS PROMOTE METASTASIS
18Apr19 07:00 RNS-R ANGLE plc Health £315.0m Parsortix used in new cancer assessment technique
12Apr19 07:00 RNS-R ANGLE plc Health £315.0m LUNG CANCER STUDY USES ANGLE'S PARSORTIX SYSTEM
04Apr19 07:00 RNS ANGLE plc Health £315.0m AACR 2019
11Mar19 07:00 RNS Legal & General Group Plc Various Various Holding(s) in Company
07Mar19 07:00 RNS ANGLE plc Health £315.0m ENROLMENT COMPLETE FOR FDA CLINICAL STUDY
28Feb19 07:00 RNS ANGLE plc Health £315.0m FIRST SUBJECTS ENROLLED IN OVARIAN CANCER STUDY
25Feb19 07:00 RNS ANGLE plc Health £315.0m CUSTOMER DEMONSTRATES NEW USE FOR PARSORTIX
11Feb19 07:00 RNS ANGLE plc Health £315.0m Research into role of immune cells in cancer
31Jan19 07:00 RNS ANGLE plc Health £315.0m Interim Results
29Jan19 07:00 RNS-R ANGLE plc Health £315.0m NEW APPLICATION FOR PARSORTIX IN CANCER ANALYSIS
10Jan19 16:01 RNS ANGLE plc Health £315.0m BREAKTHROUGH CANCER RESEARCH USING PARSORTIX
09Jan19 07:00 RNS ANGLE plc Health £315.0m Notice of Results
21Dec18 07:00 RNS ANGLE plc Health £315.0m Issue of LTIP Options and Share Options
28Nov18 07:00 RNS-R ANGLE plc Health £315.0m LEADING US HEMATOPATHOLOGIST APPOINTED AS ADVISOR
13Nov18 17:10 RNS ANGLE plc Health £315.0m Holding(s) in Company
05Nov18 07:00 RNS ANGLE plc Health £315.0m Acquisition of outstanding shares
01Nov18 07:00 RNS ANGLE plc Health £315.0m Appointment of Dr Jan Groen as NED
30Oct18 16:21 RNS ANGLE plc Health £315.0m Result of AGM
29Oct18 07:00 RNS ANGLE plc Health £315.0m PARSORTIX SHOWS CAPABILITY TO HARVEST FETAL CELLS
25Oct18 07:00 RNS ANGLE plc Health £315.0m Good Progress with FDA Studies
09Oct18 07:00 RNS ANGLE plc Health £315.0m Notice of AGM
25Jul18 07:00 RNS ANGLE plc Health £315.0m Preliminary Results for year ended 30 April 2018
24Jul18 17:42 RNS ANGLE plc Health £315.0m EIS/VCT Advance Assurance and Total Voting Rights
18Jul18 10:34 RNS ANGLE plc Health £315.0m Result of General Meeting
02Jul18 07:00 RNS ANGLE plc Health £315.0m Notice of Preliminary Results
25Jun18 18:20 RNS ANGLE plc Health £315.0m Results of Fundraising
25Jun18 14:58 RNS ANGLE plc Health £315.0m Close of Accelerated Bookbuild
25Jun18 07:50 RNS ANGLE plc Health £315.0m Proposed Placing of New Ordinary Shares
04Jun18 07:00 RNS ANGLE plc Health £315.0m ENCOURAGING PROGRESS IN ANG-002 FDA CLINICAL STUDY
19Apr18 07:00 RNS ANGLE plc Health £315.0m Breakthrough Research with Parsortix
05Apr18 07:00 RNS ANGLE plc Health £315.0m First patient enrolled in FDA study
26Mar18 07:00 RNS ANGLE plc Health £315.0m Research Update
06Feb18 07:00 RNS ANGLE plc Health £315.0m ANGLE plc: RESEARCH GRANT FROM ABBOTT
31Jan18 07:00 RNS ANGLE plc Health £315.0m Interim Results
10Jan18 10:16 RNS ANGLE plc Health £315.0m Notice of Results
08Jan18 07:00 RNS ANGLE plc Health £315.0m ANGLE plc:Prostate cancer ARV7 treatment biomarker
27Dec17 11:49 RNS ANGLE plc Health £315.0m Holding(s) in Company
12Dec17 07:00 RNS ANGLE plc Health £315.0m Transfer of Lock-in Shares
08Dec17 07:00 RNS ANGLE plc Health £315.0m PARSORTIX POTENTIAL IN METASTATIC BREAST CANCER
23Nov17 07:00 RNS ANGLE plc Health £315.0m PHILIPS COLLABORATION IN BREAST AND RECTAL CANCER
17Nov17 16:06 RNS ANGLE plc Health £315.0m Holding(s) in Company
16Nov17 08:23 RNS ANGLE plc Health £315.0m Total Voting Rights and Covington Subscription
06Nov17 07:00 RNS ANGLE plc Health £315.0m Holding(s) in Company
06Nov17 07:00 RNS ANGLE plc Health £315.0m Holding(s) in Company
06Nov17 07:00 RNS Legal & General Group Plc Various Various Holding(s) in Company
02Nov17 10:04 RNS ANGLE plc Health £315.0m Holding(s) in Company
01Nov17 08:12 RNS ANGLE plc Health £315.0m ANGLE: Completion of Fundraising and Acquisition
31Oct17 14:18 RNS ANGLE plc Health £315.0m Result of AGM
30Oct17 10:31 RNS ANGLE plc Health £315.0m Result of General Meeting
26Oct17 08:10 RNS ANGLE plc Health £315.0m Total Voting Rights
23Oct17 07:00 RNS ANGLE plc Health £315.0m Parsortix harvests cancer cells from bone marrow
20Oct17 15:05 RNS ANGLE plc Health £315.0m Notice of AGM
12Oct17 07:00 RNS ANGLE plc Health £315.0m Proposed further subscription for £2.8 million
09Oct17 07:02 RNS ANGLE plc Health £315.0m CTCs harvested with Parsortix grown in laboratory
09Oct17 07:01 RNS ANGLE plc Health £315.0m Potential new analytical protocol using Parsortix
05Oct17 11:46 RNS ANGLE plc Health £315.0m Results of Fundraising
05Oct17 07:00 RNS ANGLE plc Health £315.0m Acquisition and Fundraising
13Sep17 17:36 RNS ANGLE plc Health £315.0m Holding(s) in Company
13Sep17 07:00 RNS ANGLE plc Health £315.0m Exclusive worldwide option over megakaryocyte IP
11Sep17 07:00 RNS ANGLE plc Health £315.0m Co-Marketing Partnership with QIAGEN
05Sep17 07:00 RNS ANGLE plc Health £315.0m Change of Adviser
27Jul17 07:00 RNS ANGLE plc Health £315.0m Preliminary Results
06Jul17 10:05 RNS ANGLE plc Health £315.0m Notice of Results
04Jul17 07:00 RNS ANGLE plc Health £315.0m Successful Headline Data in Ovarian Cancer Studies
15Jun17 07:00 RNS ANGLE plc Health £315.0m Parsortix breakthrough in prostate cancer
03May17 07:00 RNS ANGLE plc Health £315.0m Business Update
04Apr17 07:00 RNS ANGLE plc Health £315.0m Holding(s) in Company
03Apr17 07:00 RNS ANGLE plc Health £315.0m Parsortix enables analysis in head and neck cancer
30Mar17 07:00 RNS ANGLE plc Health £315.0m Prostate Cancer Update
14Feb17 11:39 EQS ANGLE plc Health £315.0m Edison issues outlook on Angle
26Jan17 07:01 RNS ANGLE plc Health £315.0m Interim Evaluation of Ovarian Cancer Study
26Jan17 07:00 RNS ANGLE plc Health £315.0m Interim Results
04Jan17 07:00 RNS ANGLE plc Health £315.0m Notice of Results
28Nov16 07:00 RNS ANGLE plc Health £315.0m ISSUE OF SHARE OPTIONS
24Nov16 14:48 RNS ANGLE plc Health £315.0m Result of GM
04Nov16 07:00 RNS ANGLE plc Health £315.0m Barts Research Supports Potential Use of Parsortix
01Nov16 07:00 RNS ANGLE plc Health £315.0m Notice of GM
27Oct16 07:00 RNS ANGLE plc Health £315.0m Director's share purchase
07Oct16 11:57 RNS Legal & General Group Plc Various Various Holding(s) in Company
04Oct16 16:35 RNS ANGLE plc Health £315.0m Result of AGM
30Sep16 07:00 RNS ANGLE plc Health £315.0m Research published in Clinical Chemistry
19Sep16 11:14 RNS ANGLE plc Health £315.0m Issue of Equity
09Sep16 16:12 RNS ANGLE plc Health £315.0m Annual Report and Accounts and Notice of AGM
Date / Time Source Company % Chg
04Oct19 07:00 RNS-R ANGLE plc -1.09%
European patent granted for megakaryocyte analysis
13Sep19 07:00 RNS-R ANGLE plc -1.09%
Use of Parsortix in head and neck cancer
10Sep19 07:00 RNS ANGLE plc -1.09%
Research with Parsortix in prostate cancer
04Sep19 07:00 RNS-R ANGLE plc -1.09%
Parsortix for Neuroendocrine Analysis in SCLC
29Aug19 07:00 RNS ANGLE plc -1.09%
Initiation of Ovarian Cancer Study
31Jul19 07:00 RNS ANGLE plc -1.09%
Prelim Results for the year ended 30 April 2019
22Jul19 07:00 RNS-R ANGLE plc -1.09%
Use of Parsortix for single cell analysis of CTCs
16Jul19 09:19 RNS ANGLE plc -1.09%
Holding(s) in Company
12Jul19 10:22 RNS ANGLE plc -1.09%
Result of General Meeting anf Total Voting Rights
28Jun19 13:37 RNS ANGLE plc -1.09%
Notice of Preliminary Results and Webcast
28Jun19 13:08 RNS ANGLE plc -1.09%
Holding(s) in Company
25Jun19 17:19 RNS ANGLE plc -1.09%
Result of Placing
25Jun19 08:02 RNS ANGLE plc -1.09%
Accelerated bookbuild to raise £18.0m
21Jun19 07:00 RNS ANGLE plc -1.09%
Parsortix used to investigate immunotherapy target
05Jun19 07:00 RNS ANGLE plc -1.09%
Completion of Ovarian Cancer Pre-Study
31May19 07:00 RNS ANGLE plc -1.09%
Positive Results from FDA Clinical Study
26Apr19 07:00 RNS ANGLE plc -1.09%
IMMUNE SUPPRESSOR CELLS PROMOTE METASTASIS
18Apr19 07:00 RNS-R ANGLE plc -1.09%
Parsortix used in new cancer assessment technique
12Apr19 07:00 RNS-R ANGLE plc -1.09%
LUNG CANCER STUDY USES ANGLE'S PARSORTIX SYSTEM
04Apr19 07:00 RNS ANGLE plc -1.09%
AACR 2019
11Mar19 07:00 RNS Legal & General Group Plc -1.04%
Holding(s) in Company
07Mar19 07:00 RNS ANGLE plc -1.09%
ENROLMENT COMPLETE FOR FDA CLINICAL STUDY
28Feb19 07:00 RNS ANGLE plc -1.09%
FIRST SUBJECTS ENROLLED IN OVARIAN CANCER STUDY
25Feb19 07:00 RNS ANGLE plc -1.09%
CUSTOMER DEMONSTRATES NEW USE FOR PARSORTIX
11Feb19 07:00 RNS ANGLE plc -1.09%
Research into role of immune cells in cancer
31Jan19 07:00 RNS ANGLE plc -1.09%
Interim Results
29Jan19 07:00 RNS-R ANGLE plc -1.09%
NEW APPLICATION FOR PARSORTIX IN CANCER ANALYSIS
10Jan19 16:01 RNS ANGLE plc -1.09%
BREAKTHROUGH CANCER RESEARCH USING PARSORTIX
09Jan19 07:00 RNS ANGLE plc -1.09%
Notice of Results
21Dec18 07:00 RNS ANGLE plc -1.09%
Issue of LTIP Options and Share Options
28Nov18 07:00 RNS-R ANGLE plc -1.09%
LEADING US HEMATOPATHOLOGIST APPOINTED AS ADVISOR
13Nov18 17:10 RNS ANGLE plc -1.09%
Holding(s) in Company
05Nov18 07:00 RNS ANGLE plc -1.09%
Acquisition of outstanding shares
01Nov18 07:00 RNS ANGLE plc -1.09%
Appointment of Dr Jan Groen as NED
30Oct18 16:21 RNS ANGLE plc -1.09%
Result of AGM
29Oct18 07:00 RNS ANGLE plc -1.09%
PARSORTIX SHOWS CAPABILITY TO HARVEST FETAL CELLS
25Oct18 07:00 RNS ANGLE plc -1.09%
Good Progress with FDA Studies
09Oct18 07:00 RNS ANGLE plc -1.09%
Notice of AGM
25Jul18 07:00 RNS ANGLE plc -1.09%
Preliminary Results for year ended 30 April 2018
24Jul18 17:42 RNS ANGLE plc -1.09%
EIS/VCT Advance Assurance and Total Voting Rights
18Jul18 10:34 RNS ANGLE plc -1.09%
Result of General Meeting
02Jul18 07:00 RNS ANGLE plc -1.09%
Notice of Preliminary Results
25Jun18 18:20 RNS ANGLE plc -1.09%
Results of Fundraising
25Jun18 14:58 RNS ANGLE plc -1.09%
Close of Accelerated Bookbuild
25Jun18 07:50 RNS ANGLE plc -1.09%
Proposed Placing of New Ordinary Shares
04Jun18 07:00 RNS ANGLE plc -1.09%
ENCOURAGING PROGRESS IN ANG-002 FDA CLINICAL STUDY
19Apr18 07:00 RNS ANGLE plc -1.09%
Breakthrough Research with Parsortix
05Apr18 07:00 RNS ANGLE plc -1.09%
First patient enrolled in FDA study
26Mar18 07:00 RNS ANGLE plc -1.09%
Research Update
06Feb18 07:00 RNS ANGLE plc -1.09%
ANGLE plc: RESEARCH GRANT FROM ABBOTT
31Jan18 07:00 RNS ANGLE plc -1.09%
Interim Results
10Jan18 10:16 RNS ANGLE plc -1.09%
Notice of Results
08Jan18 07:00 RNS ANGLE plc -1.09%
ANGLE plc:Prostate cancer ARV7 treatment biomarker
27Dec17 11:49 RNS ANGLE plc -1.09%
Holding(s) in Company
12Dec17 07:00 RNS ANGLE plc -1.09%
Transfer of Lock-in Shares
08Dec17 07:00 RNS ANGLE plc -1.09%
PARSORTIX POTENTIAL IN METASTATIC BREAST CANCER
23Nov17 07:00 RNS ANGLE plc -1.09%
PHILIPS COLLABORATION IN BREAST AND RECTAL CANCER
17Nov17 16:06 RNS ANGLE plc -1.09%
Holding(s) in Company
16Nov17 08:23 RNS ANGLE plc -1.09%
Total Voting Rights and Covington Subscription
06Nov17 07:00 RNS ANGLE plc -1.09%
Holding(s) in Company
06Nov17 07:00 RNS ANGLE plc -1.09%
Holding(s) in Company
06Nov17 07:00 RNS Legal & General Group Plc -1.04%
Holding(s) in Company
02Nov17 10:04 RNS ANGLE plc -1.09%
Holding(s) in Company
01Nov17 08:12 RNS ANGLE plc -1.09%
ANGLE: Completion of Fundraising and Acquisition
31Oct17 14:18 RNS ANGLE plc -1.09%
Result of AGM
30Oct17 10:31 RNS ANGLE plc -1.09%
Result of General Meeting
26Oct17 08:10 RNS ANGLE plc -1.09%
Total Voting Rights
23Oct17 07:00 RNS ANGLE plc -1.09%
Parsortix harvests cancer cells from bone marrow
20Oct17 15:05 RNS ANGLE plc -1.09%
Notice of AGM
12Oct17 07:00 RNS ANGLE plc -1.09%
Proposed further subscription for £2.8 million
09Oct17 07:02 RNS ANGLE plc -1.09%
CTCs harvested with Parsortix grown in laboratory
09Oct17 07:01 RNS ANGLE plc -1.09%
Potential new analytical protocol using Parsortix
05Oct17 11:46 RNS ANGLE plc -1.09%
Results of Fundraising
05Oct17 07:00 RNS ANGLE plc -1.09%
Acquisition and Fundraising
13Sep17 17:36 RNS ANGLE plc -1.09%
Holding(s) in Company
13Sep17 07:00 RNS ANGLE plc -1.09%
Exclusive worldwide option over megakaryocyte IP
11Sep17 07:00 RNS ANGLE plc -1.09%
Co-Marketing Partnership with QIAGEN
05Sep17 07:00 RNS ANGLE plc -1.09%
Change of Adviser
27Jul17 07:00 RNS ANGLE plc -1.09%
Preliminary Results
06Jul17 10:05 RNS ANGLE plc -1.09%
Notice of Results
04Jul17 07:00 RNS ANGLE plc -1.09%
Successful Headline Data in Ovarian Cancer Studies
15Jun17 07:00 RNS ANGLE plc -1.09%
Parsortix breakthrough in prostate cancer
03May17 07:00 RNS ANGLE plc -1.09%
Business Update
04Apr17 07:00 RNS ANGLE plc -1.09%
Holding(s) in Company
03Apr17 07:00 RNS ANGLE plc -1.09%
Parsortix enables analysis in head and neck cancer
30Mar17 07:00 RNS ANGLE plc -1.09%
Prostate Cancer Update
14Feb17 11:39 EQS ANGLE plc -1.09%
Edison issues outlook on Angle
26Jan17 07:01 RNS ANGLE plc -1.09%
Interim Evaluation of Ovarian Cancer Study
26Jan17 07:00 RNS ANGLE plc -1.09%
Interim Results
04Jan17 07:00 RNS ANGLE plc -1.09%
Notice of Results
28Nov16 07:00 RNS ANGLE plc -1.09%
ISSUE OF SHARE OPTIONS
24Nov16 14:48 RNS ANGLE plc -1.09%
Result of GM
04Nov16 07:00 RNS ANGLE plc -1.09%
Barts Research Supports Potential Use of Parsortix
01Nov16 07:00 RNS ANGLE plc -1.09%
Notice of GM
27Oct16 07:00 RNS ANGLE plc -1.09%
Director's share purchase
07Oct16 11:57 RNS Legal & General Group Plc -1.04%
Holding(s) in Company
04Oct16 16:35 RNS ANGLE plc -1.09%
Result of AGM
30Sep16 07:00 RNS ANGLE plc -1.09%
Research published in Clinical Chemistry
19Sep16 11:14 RNS ANGLE plc -1.09%
Issue of Equity
09Sep16 16:12 RNS ANGLE plc -1.09%
Annual Report and Accounts and Notice of AGM
Date / Time Company % Chg
04Oct19 07:00 ANGLE plc -1.09%
European patent granted for megakaryocyte analysis
13Sep19 07:00 ANGLE plc -1.09%
Use of Parsortix in head and neck cancer
10Sep19 07:00 ANGLE plc -1.09%
Research with Parsortix in prostate cancer
04Sep19 07:00 ANGLE plc -1.09%
Parsortix for Neuroendocrine Analysis in SCLC
29Aug19 07:00 ANGLE plc -1.09%
Initiation of Ovarian Cancer Study
31Jul19 07:00 ANGLE plc -1.09%
Prelim Results for the year ended 30 April 2019
22Jul19 07:00 ANGLE plc -1.09%
Use of Parsortix for single cell analysis of CTCs
16Jul19 09:19 ANGLE plc -1.09%
Holding(s) in Company
12Jul19 10:22 ANGLE plc -1.09%
Result of General Meeting anf Total Voting Rights
28Jun19 13:37 ANGLE plc -1.09%
Notice of Preliminary Results and Webcast
28Jun19 13:08 ANGLE plc -1.09%
Holding(s) in Company
25Jun19 17:19 ANGLE plc -1.09%
Result of Placing
25Jun19 08:02 ANGLE plc -1.09%
Accelerated bookbuild to raise £18.0m
21Jun19 07:00 ANGLE plc -1.09%
Parsortix used to investigate immunotherapy target
05Jun19 07:00 ANGLE plc -1.09%
Completion of Ovarian Cancer Pre-Study
31May19 07:00 ANGLE plc -1.09%
Positive Results from FDA Clinical Study
26Apr19 07:00 ANGLE plc -1.09%
IMMUNE SUPPRESSOR CELLS PROMOTE METASTASIS
18Apr19 07:00 ANGLE plc -1.09%
Parsortix used in new cancer assessment technique
12Apr19 07:00 ANGLE plc -1.09%
LUNG CANCER STUDY USES ANGLE'S PARSORTIX SYSTEM
04Apr19 07:00 ANGLE plc -1.09%
AACR 2019
11Mar19 07:00 AGL LSE,LGEN LSE -1.04%
Holding(s) in Company
07Mar19 07:00 ANGLE plc -1.09%
ENROLMENT COMPLETE FOR FDA CLINICAL STUDY
28Feb19 07:00 ANGLE plc -1.09%
FIRST SUBJECTS ENROLLED IN OVARIAN CANCER STUDY
25Feb19 07:00 ANGLE plc -1.09%
CUSTOMER DEMONSTRATES NEW USE FOR PARSORTIX
11Feb19 07:00 ANGLE plc -1.09%
Research into role of immune cells in cancer
31Jan19 07:00 ANGLE plc -1.09%
Interim Results
29Jan19 07:00 ANGLE plc -1.09%
NEW APPLICATION FOR PARSORTIX IN CANCER ANALYSIS
10Jan19 16:01 ANGLE plc -1.09%
BREAKTHROUGH CANCER RESEARCH USING PARSORTIX
09Jan19 07:00 ANGLE plc -1.09%
Notice of Results
21Dec18 07:00 ANGLE plc -1.09%
Issue of LTIP Options and Share Options
28Nov18 07:00 ANGLE plc -1.09%
LEADING US HEMATOPATHOLOGIST APPOINTED AS ADVISOR
13Nov18 17:10 ANGLE plc -1.09%
Holding(s) in Company
05Nov18 07:00 ANGLE plc -1.09%
Acquisition of outstanding shares
01Nov18 07:00 ANGLE plc -1.09%
Appointment of Dr Jan Groen as NED
30Oct18 16:21 ANGLE plc -1.09%
Result of AGM
29Oct18 07:00 ANGLE plc -1.09%
PARSORTIX SHOWS CAPABILITY TO HARVEST FETAL CELLS
25Oct18 07:00 ANGLE plc -1.09%
Good Progress with FDA Studies
09Oct18 07:00 ANGLE plc -1.09%
Notice of AGM
25Jul18 07:00 ANGLE plc -1.09%
Preliminary Results for year ended 30 April 2018
24Jul18 17:42 ANGLE plc -1.09%
EIS/VCT Advance Assurance and Total Voting Rights
18Jul18 10:34 ANGLE plc -1.09%
Result of General Meeting
02Jul18 07:00 ANGLE plc -1.09%
Notice of Preliminary Results
25Jun18 18:20 ANGLE plc -1.09%
Results of Fundraising
25Jun18 14:58 ANGLE plc -1.09%
Close of Accelerated Bookbuild
25Jun18 07:50 ANGLE plc -1.09%
Proposed Placing of New Ordinary Shares
04Jun18 07:00 ANGLE plc -1.09%
ENCOURAGING PROGRESS IN ANG-002 FDA CLINICAL STUDY
19Apr18 07:00 ANGLE plc -1.09%
Breakthrough Research with Parsortix
05Apr18 07:00 ANGLE plc -1.09%
First patient enrolled in FDA study
26Mar18 07:00 ANGLE plc -1.09%
Research Update
06Feb18 07:00 ANGLE plc -1.09%
ANGLE plc: RESEARCH GRANT FROM ABBOTT
31Jan18 07:00 ANGLE plc -1.09%
Interim Results
10Jan18 10:16 ANGLE plc -1.09%
Notice of Results
08Jan18 07:00 ANGLE plc -1.09%
ANGLE plc:Prostate cancer ARV7 treatment biomarker
27Dec17 11:49 ANGLE plc -1.09%
Holding(s) in Company
12Dec17 07:00 ANGLE plc -1.09%
Transfer of Lock-in Shares
08Dec17 07:00 ANGLE plc -1.09%
PARSORTIX POTENTIAL IN METASTATIC BREAST CANCER
23Nov17 07:00 ANGLE plc -1.09%
PHILIPS COLLABORATION IN BREAST AND RECTAL CANCER
17Nov17 16:06 ANGLE plc -1.09%
Holding(s) in Company
16Nov17 08:23 ANGLE plc -1.09%
Total Voting Rights and Covington Subscription
06Nov17 07:00 ANGLE plc -1.09%
Holding(s) in Company
06Nov17 07:00 ANGLE plc -1.09%
Holding(s) in Company
06Nov17 07:00 AGL LSE,LGEN LSE -1.04%
Holding(s) in Company
02Nov17 10:04 ANGLE plc -1.09%
Holding(s) in Company
01Nov17 08:12 ANGLE plc -1.09%
ANGLE: Completion of Fundraising and Acquisition
31Oct17 14:18 ANGLE plc -1.09%
Result of AGM
30Oct17 10:31 ANGLE plc -1.09%
Result of General Meeting
26Oct17 08:10 ANGLE plc -1.09%
Total Voting Rights
23Oct17 07:00 ANGLE plc -1.09%
Parsortix harvests cancer cells from bone marrow
20Oct17 15:05 ANGLE plc -1.09%
Notice of AGM
12Oct17 07:00 ANGLE plc -1.09%
Proposed further subscription for £2.8 million
09Oct17 07:02 ANGLE plc -1.09%
CTCs harvested with Parsortix grown in laboratory
09Oct17 07:01 ANGLE plc -1.09%
Potential new analytical protocol using Parsortix
05Oct17 11:46 ANGLE plc -1.09%
Results of Fundraising
05Oct17 07:00 ANGLE plc -1.09%
Acquisition and Fundraising
13Sep17 17:36 ANGLE plc -1.09%
Holding(s) in Company
13Sep17 07:00 ANGLE plc -1.09%
Exclusive worldwide option over megakaryocyte IP
11Sep17 07:00 ANGLE plc -1.09%
Co-Marketing Partnership with QIAGEN
05Sep17 07:00 ANGLE plc -1.09%
Change of Adviser
27Jul17 07:00 ANGLE plc -1.09%
Preliminary Results
06Jul17 10:05 ANGLE plc -1.09%
Notice of Results
04Jul17 07:00 ANGLE plc -1.09%
Successful Headline Data in Ovarian Cancer Studies
15Jun17 07:00 ANGLE plc -1.09%
Parsortix breakthrough in prostate cancer
03May17 07:00 ANGLE plc -1.09%
Business Update
04Apr17 07:00 ANGLE plc -1.09%
Holding(s) in Company
03Apr17 07:00 ANGLE plc -1.09%
Parsortix enables analysis in head and neck cancer
30Mar17 07:00 ANGLE plc -1.09%
Prostate Cancer Update
14Feb17 11:39 ANGLE plc -1.09%
Edison issues outlook on Angle
26Jan17 07:01 ANGLE plc -1.09%
Interim Evaluation of Ovarian Cancer Study
26Jan17 07:00 ANGLE plc -1.09%
Interim Results
04Jan17 07:00 ANGLE plc -1.09%
Notice of Results
28Nov16 07:00 ANGLE plc -1.09%
ISSUE OF SHARE OPTIONS
24Nov16 14:48 ANGLE plc -1.09%
Result of GM
04Nov16 07:00 ANGLE plc -1.09%
Barts Research Supports Potential Use of Parsortix
01Nov16 07:00 ANGLE plc -1.09%
Notice of GM
27Oct16 07:00 ANGLE plc -1.09%
Director's share purchase
07Oct16 11:57 AGL LSE,LGEN LSE -1.04%
Holding(s) in Company
04Oct16 16:35 ANGLE plc -1.09%
Result of AGM
30Sep16 07:00 ANGLE plc -1.09%
Research published in Clinical Chemistry
19Sep16 11:14 ANGLE plc -1.09%
Issue of Equity
09Sep16 16:12 ANGLE plc -1.09%
Annual Report and Accounts and Notice of AGM